Novartis cuts 500 traditional roles for 350 ‘high-tech’ ones

pharmafile | May 22, 2017 | News story | Manufacturing and Production, Research and Development, Sales and Marketing Novartis 

Novartis has announced a restructure within the company which will lead to the transfer or loss of 500 traditional production and development roles at its Swiss sites as it looks to add 350 others in high tech areas including “development and innovative biologics manufacturing”.

Part of its wider global restructuring efforts, the move is the biggest of its kind planned by the company through to the end of 2018, though smaller reshuffles could not be ruled out. The company stated that these actions illustrated their commitment to manufacturing in Switzerland – its native country. It will lead to around 150 jobs losses which it notes are part of plans launched last year to harmonise operations and “lead to personnel adjustments in various countries”.   

The plan is due to take place over 18 months and will see the closure of production sites in Basel, including the facility at the Schweizerhalle industrial complex. It is thought that some operational capacity may be relocated to India.

Novartis employs approximately 120,000 staff worldwide. In October last year, the company announced it was axing 175 roles related to its research programmes in Switzerland and China as part of a cost-cutting effort to centralise its drug discovery ventures.

Matt Fellows

Related Content

Novartis shares new data about Fabhalta for IgAN treatment

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …

chuttersnap-oijvdm3zx4i-unsplash

Novartis shares new data for Zolgensma in children with SMA

Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …

Novartis to acquire MorphoSys AG for €2.7bn

Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, …

Latest content